iSpecimen (ISPC) AI Stock Analysis

• Market Cap: $3.12M
• Dividend Yield: N/A
• Average Volume (3M): 103.35K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.15
• Revenue Growth: -6.42%
• EPS Growth: 24.85%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 57
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -18.45
• Shares Outstanding: 2,496,858
• 10 Day Avg. Volume: 23,177
• 30 Day Avg. Volume: 103,353
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.67
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

iSpecimen's overall stock score is low due to significant financial performance issues, including declining revenues and negative cash flows. The bearish technical indicators also contribute to the negative outlook. Additionally, the lack of profitability and dividend yield severely impacts the stock's valuation. Strategic interventions are necessary to address these challenges and improve the company's financial health.

iSpecimen Business Overview & Revenue Model

Company Description

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

iSpecimen makes money primarily through transaction fees charged to researchers and organizations that procure biospecimens via its platform. The company partners with hospitals, laboratories, and biobanks to source diverse and high-quality specimens, creating a robust supply chain. Revenue is generated from the fees applied to each transaction facilitated on their marketplace, and they may also earn through subscription or service fees for access to additional platform features. Strategic partnerships with healthcare providers enhance their specimen network, contributing to the company's ability to attract more researchers and drive transactions.

iSpecimen Financial Statement Overview

Summary

iSpecimen is facing significant financial challenges with consistent net losses and negative cash flows. While there are some improvements in operational margins, financial stability remains a concern due to historical negative equity and declining revenues. The company needs to improve its revenue trajectory and cash flow management to enhance its financial health.

Income Statement

The company shows declining revenue with a negative revenue growth rate of -5.13% from the previous year. Gross profit margin is relatively low at 31.22% TTM, and the net profit margin is negative, reflecting consistent losses. There is an improvement in EBITDA margin from -91.69% to -69.47% TTM, indicating some operational efficiency gains.

Balance Sheet

The debt-to-equity ratio is 0.25 TTM, suggesting manageable leverage. However, the company has negative equity in past years, indicating financial instability. The current equity ratio is 41.86% TTM, which is a positive sign of asset financing through equity, but return on equity is negative due to net losses.

Cash Flow

The company has a negative free cash flow growth rate of -48.81% TTM, which is concerning. Operating cash flow to net income ratio of 0.46 suggests moderate conversion of net income to cash. Free cash flow to net income ratio is unfavorable due to negative values, highlighting cash constraints.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.29M	9.93M	10.40M	11.14M	8.18M
	Gross Profit
3.99M	5.11M	5.65M	5.89M	4.60M
	EBIT
-12.73M	-11.17M	-10.19M	-5.93M	-2.41M
	EBITDA
-12.73M	-9.10M	-8.80M	-5.86M	-1.74M
	Net Income Common Stockholders
-12.50M	-11.10M	-9.04M	-10.02M	-6.76M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.88M	5.01M	15.31M	27.74M	695.91K
	Total Assets
9.35M	15.82M	24.62M	35.72M	6.21M
	Total Debt
312.17K	196.24K	185.85K	3.42M	12.77M
	Net Debt
-1.57M	-2.15M	-15.12M	-24.32M	12.07M
	Total Liabilities
6.04M	6.08M	4.31M	5.93M	33.49M
	Stockholders Equity
3.31M	9.74M	20.31M	29.79M	-27.28M
Cash Flow		Free Cash Flow
-8.30M	-10.55M	-9.01M	-11.71M	-1.39M
	Operating Cash Flow
-8.26M	-5.81M	-5.82M	-10.67M	-288.38K
	Investing Cash Flow
1.98M	-7.23M	-3.19M	-1.04M	-1.10M
	Financing Cash Flow
5.82M	70.89K	-3.42M	38.75M	2.03M

iSpecimen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.35, and below the 200-day MA of 3.46, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.99 is Neutral, neither overbought nor oversold. The STOCH value of 80.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.

iSpecimen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%
APDN	42 Neutral	$5.79M	―	-100.40%	―	-58.46%	47.98%
ISPC	39 Underperform	$3.12M	―	-191.51%	―	-6.42%	24.85%
AWHL	39 Underperform	$2.08M	―		―	0.31%	44.72%
NDRA	34 Underperform	$3.45M	―	-280.02%	―	―	71.89%
CHEK	26 Underperform	$4.45M	―	-74.17%	―	―	―

iSpecimen Corporate Events

iSpecimen Announces Key Leadership Appointments

On February 19, 2025, iSpecimen Inc. announced significant leadership changes with the appointment of Ms. Katharyn Field as President, who resigned from the Board, and Ms. Siyun Yang stepping in as an independent director. Ms. Yang, with her extensive legal background, will serve on the Audit and Nominating and Corporate Governance Committees, enhancing the Board’s oversight capabilities. The Board also appointed Mr. Richard Paolone as Chair, with Mr. Robert Bradley Lim continuing as CEO. These changes are not expected to disrupt the company’s operations.